Photobiomodulation therapy inhibits oral submucous fibrosis in mice

Chiang, Min‐Hsuan; Lee, Kun-Tsung; Chen, Chia‐Hsin; Chen, Ker‐Kong; Wang, Yan‐Hsiung

doi:10.1111/odi.13409

Cited by 12 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sub-buccal administration of areca nut extract (ANE, 100 µL, 20 mg/mL) was given at the left buccal mucosa of rats on an alternate day for 60 days (Chiang et al 2020 ). The control group of rats ( n = 6) did not received ANE, instead water for injection was applied topically thrice a day.…”

Section: Methodsmentioning

confidence: 99%

Polyphenol-based targeted therapy for oral submucous fibrosis

Mehta¹,

Paliwal²,

Muttigi³

et al. 2023

Inflammopharmacol

View full text Add to dashboard Cite

Oral submucous fibrosis (OSF) is a chronic, progressive, and precancerous condition mainly caused by chewing areca nut. Currently, OSF therapy includes intralesional injection of corticosteroids with limited therapeutic success in disease management. Therefore, a combined approach of in silico, in vitro and in vivo drug development can be helpful. Polyphenols are relatively safer than other synthetic counterparts. We used selected polyphenols to shortlist the most suitable compound by in silico tools. Based on the in silico results, epigallocatechin-3-gallate (EGCG), quercetin (QUR), resveratrol, and curcumin had higher affinity and stability with the selected protein targets, transforming growth factor beta-1 (TGF-β1), and lysyl oxidase (LOX). The efficacy of selected polyphenols was studied in primary buccal mucosal fibroblasts followed by in vivo areca nut extract induced rat OSF model. In in vitro studies, the induced fibroblast cells were treated with EGCG and QUR. EGCG was safer at higher concentrations and more efficient in reducing TGF-β1, collagen type-1A2 and type-3A1 mRNA expression than QUR. In vivo studies confirmed that the EGCG hydrogel was efficient in improving the disease conditions compared to the standard treatment betamethasone injection with significant reduction in TGF-β1 and collagen concentrations with increase in mouth opening. EGCG can be considered as a potential, safer and efficient phytomolecule for OSF therapy and its mucoadhesive topical formulation help in the improvement of patient compliance without any side effects. Graphical abstract Highlights Potential polyphenols were shortlisted to treat oral submucous fibrosis (OSF) using in silico tools Epigallocatechin 3-gallate (EGCG) significantly reduced TGF-β1 and collagen both in vitro and in vivo EGCG hydrogel enhanced antioxidant defense, modulated inflammation by reducing TGF-β1 and improved mouth opening in OSF rat model.

show abstract

Section: Methodsmentioning

confidence: 99%

Polyphenol-based targeted therapy for oral submucous fibrosis

Mehta¹,

Paliwal²,

Muttigi³

et al. 2023

Inflammopharmacol

View full text Add to dashboard Cite

show abstract

“… 25 In short, the rats were injected subbuccal with 0.2 mL arecoline hydrobromide dissolved in 0.9% normal saline every two days (10 mg/mL, B20112, Shanghai Yuanye Bio-Technology Co., Ltd). 26 JDK was provided by The First Affiliated Hospital of Hunan University of Chinese Medicine and composed of 10g Salvia miltiorrhiza Bunge , 10g Scrophularia ningpoensis Hemsl , 10g Angelica sinensis (Oliv.) Diels , 5g Carthamus tinctorius Linn , 10g Rehmannia henryi N. E. Brown , 10g Hedyotis diffusa Willd , 10g Astragalus saxorum Simps , 10g Mentha haplocalyx Briq , 10g Platycodon grandiflorus (Jacq.)…”

Section: Methodsmentioning

confidence: 99%

Jiawei Danxuan Koukang Alleviates Arecoline Induced Oral Mucosal Lesions: Network Pharmacology and the Combined Ultra-High Performance Liquid Chromatography (UPLC) and Mass Spectrometry (MS)

Zhou,

Tan,

Dai

et al. 2023

DDDT

View full text Add to dashboard Cite

Purpose Arecoline is one of the main toxic components of arecoline to cause oral mucosal lesions or canceration, which seriously affects the survival and life quality of patients. This study analyzed the mechanism of Jiawei Danxuan Koukang (JDK) in alleviating arecoline induced oral mucosal lesions, to provide new insights for the treatment of oral submucosal fibrosis (OSF) or cancerosis. Methods Metabolomics was applied to analyze the composition of JDK and serum metabolites. The active ingredients of JDK were analyzed by the combined ultra-high performance liquid chromatography and mass spectrometry. The target network of JDK, metabolites and OSF was analyzed by network pharmacology, and molecular docking. Oral mucosal lesions and fibrosis were analyzed by HE and Masson staining. Cell differentiation, proliferation and apoptosis were detected. The expressions of α-SMA, Collagen I, Vimentin, Snail, E-cadherin, AR and NOTCH1 were detected by Western blot. Results Arecoline induced the gradual atrophy and thinning of rat oral mucosal, collagen accumulation, the increase expressions of fibrosis-related proteins and Th17/Treg ratio. JDK inhibited arecoline-induced oral mucosal lesions and inflammatory infiltration. Arecoline induced changes of serum metabolites in Aminoacyl-tRNA biosynthesis, Alanine, aspartate and glutamate metabolism and Arginine biosynthesis pathways, which were reversed by M-JDK. Quercetin and AR were the active ingredients and key targets of JDK, metabolites and OSF interaction. Arecoline promoted the expression of AR protein, and the proliferation of oral fibroblasts. Quercetin inhibited the effect of arecoline on oral fibroblasts, but was reversed by AR overexpression. Arecoline induced NOTCH1 expression in CAL27 and SCC-25 cells, and promoted cell proliferation, but was reversed by M-JDK or quercetin. Conclusion JDK improved the arecoline-induced OSF and serum metabolite functional pathway. Quercetin targeted AR protein to improve arecoline-induced OSF. JDK and quercetin inhibited arecoline-induced NOTCH1 protein expression in CAL27 and SCC-25 cells to play an anti-oral cancer role.

show abstract

“…2. Sub-buccal injection of (100 µL, 20 mg/mL) ANE was given at left buccal mucosal tissue of rats for induction of OSF for 2 months, followed by treatment of disease-induced rats with optimized formulations [9,24]. The standard treatment was betamethasone injection (BTM Inj.…”

Section: Preparation and Evaluation Of Plga Nanoparticles And Hydroge...mentioning

confidence: 99%

Development of Epigallocatechin 3-gallate-Loaded Hydrogel Nanocomposites for Oral Submucous Fibrosis

Mehta,

Velagacherla,

Manandhar

et al. 2024

AAPS PharmSciTech

View full text Add to dashboard Cite

Oral submucous fibrosis (OSF) is a chronic progressive disease associated with increased collagen deposition and TGF-β1 release. The current therapy and management have been a limited success due to low efficacy and adverse drug reactions. This study aimed to evaluate epigallocatechin 3-gallate (EGCG) encapsulated nanoparticles loaded mucoadhesive hydrogel nanocomposite (HNC) for OSF. Developed HNC formulations were evaluated for their permeation behaviour using in vitro as well as ex vivo studies, followed by evaluation of efficacy and safety by in vivo studies using areca nut extract-induced OSF in rats. The disease condition in OSF-induced rats was assessed by mouth-opening and biochemical markers. The optimized polymeric nanoparticles exhibited the required particle size (162.93 ± 13.81 nm), positive zeta potential (22.50 ± 2.94 mV) with better mucoadhesive strength (0.40 ± 0.002 N), and faster permeation due to interactions of the positively charged surface with the negatively charged buccal mucosal membrane. HNC significantly improved disease conditions by reducing TGF-β1 and collagen concentration without showing toxicity and reverting the fibroid buccal mucosa to normal. Hence, the optimized formulation can be further tested to develop a clinically alternate therapeutic strategy for OSF. Graphical Abstract

show abstract

Photobiomodulation therapy inhibits oral submucous fibrosis in mice

Cited by 12 publications

References 34 publications

Polyphenol-based targeted therapy for oral submucous fibrosis

Polyphenol-based targeted therapy for oral submucous fibrosis

Jiawei Danxuan Koukang Alleviates Arecoline Induced Oral Mucosal Lesions: Network Pharmacology and the Combined Ultra-High Performance Liquid Chromatography (UPLC) and Mass Spectrometry (MS)

Development of Epigallocatechin 3-gallate-Loaded Hydrogel Nanocomposites for Oral Submucous Fibrosis

Contact Info

Product

Resources

About